Savara Inc (NASDAQ:SVRA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Savara Inc (NASDAQ:SVRA) have earned a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $8.83.

A number of research analysts recently weighed in on SVRA shares. JMP Securities restated a “market outperform” rating and set a $9.00 price objective on shares of Savara in a research report on Thursday, December 19th. Wells Fargo & Company initiated coverage on Savara in a research note on Friday, December 20th. They issued an “overweight” rating and a $8.00 price target on the stock.

Savara Price Performance

SVRA opened at $2.82 on Monday. The company’s 50-day simple moving average is $2.73 and its two-hundred day simple moving average is $3.30. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. The stock has a market capitalization of $483.97 million, a P/E ratio of -6.56 and a beta of 0.60. Savara has a 52-week low of $2.26 and a 52-week high of $5.34.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Cibc World Markets Corp purchased a new stake in shares of Savara in the 4th quarter worth $33,000. XTX Topco Ltd bought a new stake in Savara during the fourth quarter valued at about $34,000. Ameriprise Financial Inc. purchased a new stake in Savara in the fourth quarter worth about $37,000. KLP Kapitalforvaltning AS bought a new position in shares of Savara in the fourth quarter worth about $41,000. Finally, Hsbc Holdings PLC purchased a new position in shares of Savara during the 4th quarter valued at about $48,000. 87.93% of the stock is currently owned by institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.